Xpantoz-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed for the effective management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief and promoting mucosal healing in acid-related conditions. The synergistic action of these two agents addresses both the underlying hyperacidity and motility disturbances, offering comprehensive symptom control. Xpantoz-DSR is indicated for patients experiencing frequent heartburn, acid regurgitation, and upper abdominal discomfort associated with GERD, erosive esophagitis, and functional dyspepsia. It is generally well tolerated, with adverse effects being infrequent and mild, including headache, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. The medication should be administered as prescribed by a healthcare professional, with adherence to recommended dosage and duration to optimize therapeutic outcomes and minimize potential risks.